High-Throughput Screening (HTS) enabled Drug Screening Service on Advanced Functional CAR-T Model

Online Inquiry

Background Service What we can offer Workflow Highlights FAQsCustomer Reviews Contact

Accelerate Your CAR-T Discovery! Are you currently facing long development cycles, difficulty predicting CAR-T efficacy, or challenges in identifying synergistic compounds? Our High-throughput screening (HTS)-enabled Drug Screening Service on Advanced Functional CAR-T Models helps you rapidly evaluate drug interactions, optimize CAR-T functionality, and uncover combination strategies through high-throughput screening, multi-dimensional functional readouts, and advanced tumor modeling.

Introduction

HTS-enabled drug screening on advanced functional CAR-T models integrates high-throughput platforms with physiologically relevant CAR-T assays. The studies demonstrate that combining cytotoxicity, cytokine release, and phenotypic readouts allows identification of compounds that enhance CAR-T efficacy or reduce exhaustion. This approach accelerates preclinical evaluation while providing actionable insights for therapy optimization.

Service

Creative Biolabs provides a comprehensive, high-throughput platform to assess CAR-T functionality under complex tumor-like conditions.

Functional Assessment: Track CAR-T cytotoxicity, cytokine release, proliferation, and exhaustion across tumor models in real time to reveal immune-tumor dynamics and functional durability.
Drug Interaction Screening: Test small molecules, biologics, or combinations to identify synergistic or inhibitory effects, optimize CAR-T persistence, infiltration, and tumor-killing efficiency, with dose-response and off-target evaluation.
Predictive Insights: Apply multi-parameter analyses and bioinformatics to guide CAR-T design, combination strategies, and clinical translation, uncovering optimal candidates, resistance mechanisms, and ways to overcome tumor microenvironment immunosuppression.

Discover How We Can Help - Request a Consultation.

What we can offer

Our service leverages multiple technologies to deliver robust functional CAR-T screening:

Platform of HTS-enabled Drug Screening. (Creative Biolabs Original)

Our Process

Required Starting Materials:

CAR-T cell constructs or pre-engineered CAR-T lines.

Tumor cell lines or primary tumor samples for co-culture assays.

Candidate libraries or biologics for screening.

Workflow of HTS-enabled Drug Screening. (Creative Biolabs Original)

Final Deliverables: Cytotoxicity kinetics and cytokine release datasets and phenotypic profiling of CAR-T differentiation and exhaustion.

Key Benefits

High-Throughput Functional Screening: Automated workflows combined with functional CAR-T assays enable rapid screening of large compound libraries while retaining key readouts such as cytotoxicity, cytokine release, and exhaustion markers.
Tumor-Relevant Models: Complex tumor-like conditions, including variable antigen expression and immune-suppressive features, enhance the predictive relevance of screening results.
Multi-Parameter Readouts: Parallel measurement of functional and phenotypic endpoints provides a comprehensive view of CAR-T performance beyond single assays.
Flexible Customization: Assays, CAR constructs, tumor models, and screening scale can be adapted to specific project requirements across development stages.

FAQs

Q1: Can this service be applied to early-stage CAR-T candidates?

A1: Yes. The HTS-enabled Drug Screening Service on Advanced Functional CAR-T Models is well suited for early-stage discovery. It enables rapid functional benchmarking of multiple CAR constructs and helps prioritize the most promising candidates before committing to resource-intensive studies.

Q2: What types of compounds can be evaluated in this screening platform?

A2: The platform supports screening of diverse compound classes, including small molecules, biologics, and combination regimens. This flexibility allows clients to explore synergistic strategies that enhance CAR-T efficacy or durability under tumor-like conditions.

Q3: How does this approach differ from conventional CAR-T functional assays?

A3: Unlike low-throughput or single-endpoint assays, this service integrates high-throughput workflows with multi-parameter functional readouts. It captures cytotoxicity, cytokine release, and exhaustion profiles simultaneously, providing a more predictive and clinically relevant assessment.

Customer Reviews

"Using Creative Biolabs' HTS-enabled Drug Screening Service on Advanced Functional CAR-T Models in our research has improved candidate prioritization for CAR-T combination therapy development. The ability to compare functional durability across compounds saved us substantial time."

— Dr. Li***

"Using Creative Biolabs' HTS-enabled Drug Screening Service on Advanced Functional CAR-T Models has facilitated our evaluation of CAR-T performance under immune-suppressive conditions. Compared with conventional assays, the data were more predictive and directly informed our in vivo study design."

— Chen***

Partner with Us

Creative Biolabs delivers an integrated HTS-enabled Drug Screening Service on Advanced Functional CAR-T Models, combining high-throughput capacity with biologically relevant functional assays. The service supports CAR-T optimization, compound prioritization, and combination strategy development through data-rich, actionable outputs designed to accelerate preclinical progress.

To explore how Creative Biolabs can support your CAR-T development and drug screening objectives, our scientific team is ready to assist. Contact Our Team to discuss how early integration can streamline your pipeline.

Reference

Si, Xiaohui et al. "Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models." International journal of molecular sciences vol. 23,6 3154. 15 Mar. 2022. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/ijms23063154

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.